124 related articles for article (PubMed ID: 7634247)
1. Interferon-alpha-induced protection of renal cell cancer cell line from lysis by natural killer cells and increase of susceptibility by treatment with 5-fluorouracil.
Imai T; Katagiri A; Saito K; Tomita Y
Cancer Lett; 1995 Aug; 94(2):191-7. PubMed ID: 7634247
[TBL] [Abstract][Full Text] [Related]
2. 5-Fluorouracil increases susceptibility of renal cell cancer cell lines to lymphokine-activated killer cells: evidence for alteration not at the level of recognition but at a post-binding stage of the lytic cycle.
Tomita Y; Imai T; Katagiri A; Kimura M; Saitoh K; Sato S
Cancer Lett; 1993 Nov; 75(1):27-34. PubMed ID: 7904537
[TBL] [Abstract][Full Text] [Related]
3. Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.
Tomita Y; Watanabe H; Kobayashi H; Nishiyama T; Tsuji S; Fujiwara M; Sato S
Cancer Immunol Immunother; 1992; 35(6):381-7. PubMed ID: 1356627
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.
Sella A; Kilbourn RG; Gray I; Finn L; Zukiwski AA; Ellerhorst J; Amato RJ; Logothetis CJ
Cancer Biother; 1994; 9(2):103-11. PubMed ID: 7812360
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells.
de Fries RU; Golub SH
J Immunol; 1988 May; 140(10):3686-93. PubMed ID: 3129500
[TBL] [Abstract][Full Text] [Related]
6. [Interferon-induced protection of renal cell cancer cell lines to lymphokine-activated killer (LAK) cells and effect of acid treatment on their susceptibility. Its relevance to expression of major histocompatibility complex class I antigens on tumor cells].
Tomita Y; Kimura M; Nishiyama T; Sato S
Nihon Hinyokika Gakkai Zasshi; 1991 May; 82(5):762-8. PubMed ID: 1908533
[TBL] [Abstract][Full Text] [Related]
7. A dual anti-tumor effect of a combination of interferon-alpha or interleukin-2 and 5-fluorouracil on natural killer (NK) cell-mediated cytotoxicity.
Reiter Z; Ozes ON; Blatt LM; Taylor MW
Clin Immunol Immunopathol; 1992 Jan; 62(1 Pt 1):103-11. PubMed ID: 1370257
[TBL] [Abstract][Full Text] [Related]
8. Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes.
Mizutani Y; Bonavida B; Fukumoto M; Yoshida O
J Immunother Emphasis Tumor Immunol; 1995 Feb; 17(2):78-87. PubMed ID: 7647959
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
[TBL] [Abstract][Full Text] [Related]
10. Renal carcinoma cell lines inhibit natural killer activity via the CD94 receptor molecule.
Stanley AJ; Gough MJ; Banks RE; Selby PJ; Patel PM
Cancer Immunol Immunother; 2001 Jul; 50(5):260-8. PubMed ID: 11499809
[TBL] [Abstract][Full Text] [Related]
11. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of phorbol ester and interferon-alpha: target cell class I HLA antigen expression and resistance to natural killer and lymphokine-activated killer cell-mediated cytolysis.
Migita K; Eguchi K; Akiguchi I; Ida H; Kawakami A; Ueki Y; Kurata A; Fukuda T; Nagataki S
Cell Immunol; 1991 May; 134(2):325-35. PubMed ID: 2021973
[TBL] [Abstract][Full Text] [Related]
13. [Lysis of autologous tumor cells by peripheral blood lymphocytes treated with IFN-alpha in patients with renal cell carcinoma].
Kubota S
Nihon Hinyokika Gakkai Zasshi; 1992 Nov; 83(11):1781-8. PubMed ID: 1479751
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma-induced alterations of monocyte susceptibility to lysis by autologous lymphokine-activated killer (LAK) cells.
Djeu JY; Blanchard DK
Int J Cancer; 1988 Sep; 42(3):449-54. PubMed ID: 3138195
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of interferon gamma-induced protection of human gliosarcoma cells from lymphokine-activated killer lysis: division of lymphokine-activated killer cells into natural killer- and T-like cells.
Kondo S; Miyatake S; Kikuchi H; Oda Y; Iwasaki K; Ohyama K; Namba Y
Neurosurgery; 1992 Sep; 31(3):534-40. PubMed ID: 1407434
[TBL] [Abstract][Full Text] [Related]
16. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic in vitro function in patients with metastatic renal cell carcinoma before and after alpha-2b-interferon therapy. Effects of activation with recombinant interleukin-2.
Feruglio C; Zambello R; Trentin L; Bulian P; Franceschi T; Cetto GL; Semenzato G
Cancer; 1992 May; 69(10):2525-31. PubMed ID: 1568175
[TBL] [Abstract][Full Text] [Related]
18. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
19. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
Blanchard DK; Djeu JY
J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor reactivity of human lymphokine activated killer (LAK) cells against fresh and cultured preparations of renal cell cancer.
Belldegrun A; Uppenkamp I; Rosenberg SA
J Urol; 1988 Jan; 139(1):150-5. PubMed ID: 3257274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
